新型蛋白质配体-亲和体研究进展

被引：2

作者：

李爽

郝志明

机构：

[1] 西安交通大学医学院第一附属医院

来源：

生物化学与生物物理进展 | 2012年 / 39卷 / 02期

关键词：

亲和体; 人工突变; 体外筛选; 分子影像学;

D O I：

暂无

中图分类号：

Q51 [蛋白质];

学科分类号：

摘要：

亲和体(affibody)是一种衍生于葡萄球菌A蛋白B结构域的人工蛋白质分子.B结构域含58个氨基酸,形成3个α螺旋结构,分子质量约为6.5 ku.其中第一及第二螺旋中的13个特定位点的氨基酸对其结构无明显影响,这些位点可被随机突变形成理论上可与任何靶分子结合的亲和体文库.筛选该文库可获得能与某一靶分子特异结合的亲和体.亲和体与靶分子的结合特性与抗体相似,但与抗体相比具有一些独特的优势,如:通过体外筛选即可获得,以化学合成方法或原核表达即可大量制备,分子质量小、在生物体内组织穿透性强、血浆清除率高,理化稳定性好,可以通过交联或融合表达与标记分子(如荧光蛋白、生物素等)结合而不影响其与靶分子的结合能力.亲和体可作为抗体的替代品,用于蛋白质识别、分离及纯化、实验诊断、分子显像及靶向治疗.

引用

页码：137 / 141

页数：5

共 28 条

[1] Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain. Vernet E,Lundberg E,Friedman M,et al. Nature Biotechnology . 2009
[2] Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. Belousova N,Mikheeva G,Gelovani J,et al. Journal of Virology . 2008
[3] Decreased immune reactivity towards a knobless,affibody-targeted adenovirus type5vector. Myhre S,Henning P,Granio O,et al. Gene Therapy . 2007
[4] Radionuclide therapy of HER2-positive microxenografts using a Lu-177-labeled HER2-specific affibody molecule. Tolmachev V,Orlova A,Pehrson R,et al. Cancer Research . 2007
[5] Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. R?nnmark,J,Kampf,C,Asplund,A,H?iden-Guthenberg,I,Wester,K,Ponten,F. Journal of Immunological Methods . 2003
[6] Adenovirus 5 vectorgenetically re-targeted by an Affibody molecule with specificity fortumor antigen HER2/neu. Magnusson MK,Henning P,Myhre S,et al. Cancer Gene Therapy . 2007
[7] HER-2-Targeted Nanoparticle-affibody bioconjugates for cancer therapy. Alexis, F,Basto, P,Levy-Nissenbaum, E. Chemmedchem . 2008
[8] Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. A Orlova,M Magnusson,T Eriksson,M Nilsson,B Larsson,I H?idén-Guthenberg,C Widstr?m,J Carlsson,V Tolmachev,S St?hl,FY Nilsson. Cancer Research . 2006
[9] Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. E Lundberg,I H?idén-Guthenberg,B Larsson,M Uhlén,T Gr?slund. Journal of Immunological Methods . 2007
[10] In vitro selection and evolution of functional proteins by using ribosome display. Hanes J,Pluckthun A. Proceedings of the National Academy of Sciences of the United States of America . 1997

← 1 2 3 →